Market Place
Sourcing Support
Alexion`s Biologic Ultomiris (Ravulizumab) Receives Suppl Approval in US
19 Sep 2024 //
FDA
Alexion`s Biologic Ultomiris (ravulizumab-cwvz) Receives Approvals in the US
28 Jun 2024 //
FDA
Voydeya approved in the EU as add-on treatment to ravulizumab
23 Apr 2024 //
PRESS RELEASE
AZ`s Alexion debuts short film highlighting NMOSD community
18 Apr 2024 //
FIERCE PHARMA
Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya
08 Apr 2024 //
GLOBENEWSWIRE
FDA clears AZ’s new PNH therapy Voydeya
01 Apr 2024 //
PRESS RELEASE
FDA expands AZ`s Ultomiris to NMOSD after prior rejection
26 Mar 2024 //
FIERCE PHARMA
ULTOMIRIS approved in the US for the treatment of adults with NMOSD
25 Mar 2024 //
BUSINESSWIRE
Voydeya recommended for approval in the EU by CHMP
26 Feb 2024 //
PRESS RELEASE
PIII trial data showed danicopan as add-on to ULTOMIRIS sustained improvements
10 Dec 2023 //
BUSINESSWIRE
FDA Rejects AstraZeneca’s Ultomiris Label Expansion in NMOSD
07 Sep 2023 //
BIOSPACE
The Evolving Treatment Landscape in Paroxysmal Nocturnal Hemoglobinuria
30 Jun 2023 //
ONCLIVE
AZ’s Ultomiris approved in Japan for prevention of relapses in patients NMOSD
30 May 2023 //
PHARMATIMES
AstraZeneca’s Ultomiris receives Jpanese approval for prevention of NMOSD
27 May 2023 //
PHARMABIZ
AstraZeneca’s Ultomiris receives Japanese approval for NMOSD
26 May 2023 //
PHARMACEUTICAL TECHNOLOGY
AZ showcases advances across rare and malignant haematological conditions
17 May 2023 //
PHARMABIZ
EU approves Ultomiris for adults with neuromyelitis optica spectrum disorder
11 May 2023 //
PHARMABIZ
Ultomiris approved in the EU for adults with NMOSD
10 May 2023 //
PRESS RELEASE
Ultomiris recommended for approval in the EU by CHMP for NMOSD
04 Apr 2023 //
PRESS RELEASE
ULTOMIRIS showed zero relapses in adults with NMOSD
27 Oct 2022 //
BUSINESSWIRE
Phase III CHAMPION-NMOSD trial of Ultomiris shows zero relapses in adults NMOSD
27 Oct 2022 //
PHARMABIZ
Alexion aims to advance NMOSD treatment landscape with ULTOMIRIS efficacy data
12 Oct 2022 //
BUSINESSWIRE
EC approves Alexion’s Ultomiris for generalised myasthenia gravis
27 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Ultomiris approved in Europe for the treatment of generalised myasthenia gravis
23 Sep 2022 //
PRESS RELEASE
Danicopan Add-On to ULTOMIRIS or SOLIRIS Met Primary Endpoint in ALPHA PIII
16 Sep 2022 //
BUSINESSWIRE
Danicopan (ALXN2040) Add-On to ULTOMIRIS® or SOLIRIS® (eculizumab)
16 Sep 2022 //
BIOSPACE
AstraZeneca Scores Japanese Approvals in NSCLC, gMG and Breast Cancer
26 Aug 2022 //
BIOSPACE
Ultomiris approved in Japan for the treatment of myasthenia gravis
25 Aug 2022 //
PRESS RELEASE
Argenx`s Vyvgart and Alexion`s Ultomiris Go Toe-to-Toe in Myasthenia Gravis
24 Aug 2022 //
PRNEWSWIRE
On a roll, AstraZeneca flags looming approvals for three big drug franchises
26 Jul 2022 //
ENDPTS
ULTOMIRIS Approved in US for Adults with Generalized Myasthenia Gravis
28 Apr 2022 //
BUSINESSWIRE
Alexion Pharmaceuticals`s Ravulizumab Receives Supplemental Approval in U.S.
27 Apr 2022 //
FDA
ULTOMIRIS shows sustained improvements in functional activities, quality of life
06 Apr 2022 //
BUSINESSWIRE
Roche, AstraZeneca settle Ultomiris patent lawsuit
19 Feb 2022 //
FIERCEPHARMA
Ultomiris regulatory submission accepted under FDA Priority Review
21 Dec 2021 //
ASTRAZENECA
Alexion`s Generic Ultomiris (Ravulizumab) Receives Approval in the US
22 Nov 2021 //
FDA
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS
15 Jul 2021 //
BUSINESS WIRE
Alexion`s Ultomiris gets FDA nod to treat PNH in paediatric patients
07 Jun 2021 //
BUSINESSWIRE
Alexion Announces FDA Approval of ULTOMIRIS for Children and Adolescents
07 Jun 2021 //
BUSINESSWIRE
Apellis to Present Long-Term Pegcetacoplan Data at the EHA Congress
12 May 2021 //
GLOBENEWSWIRE
Alexion Pharm`s Biological Ravulizumab-Cwvz Receives Approval In US
22 Apr 2021 //
FDA
NICE recommends Alexion’s long-acting Ultomiris for PNH
16 Apr 2021 //
PHARMAPHORUM
Alexion and NICE agree confidential discount for Ultomiris use on the NHS
16 Apr 2021 //
PMLIVE
Alexion wins NICE backing for Ultomiris in PNH
16 Apr 2021 //
FIERCE PHARMA
NICE backs Ultomiris for adult patients with PNH
15 Apr 2021 //
NEUROEUROPE
Korean biotech company liable in gene therapy dispute
14 Jan 2021 //
GLOBALARBITRATIONREVIEW
Alexion`s Ultomiris shows "lack of efficacy" in severe COVID-19 study
14 Jan 2021 //
BLOOMBERG
Alexion Provides Update on Phase 3 Study of ULTOMIRIS®
13 Jan 2021 //
BUSINESSWIRE
Alexion`s new, quicker-infusing Ultomiris formula snares FDA nod
16 Oct 2020 //
FIERCE PHARMA
Alexion`s Ultomiris (Ravulizumab-cwvz) Receives Supplemental Approval in US
14 Oct 2020 //
FDA
Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS®
12 Oct 2020 //
PRESS RELEASE
Alexion`s Ultomiris Recieves Approval in Japan
25 Sep 2020 //
SEEKING ALPHA
Alexion Pharma`s ULTOMIRIS® (ravulizumab) Receives Approval in Japan
25 Sep 2020 //
BUSINESSWIRE
EMA committee recommends marketing approval of Alexion’s new 100 mg/mL IV
21 Sep 2020 //
PHARMABIZ
Alexion Receives CHMP Positive Opinion For New Formulation Of Ravulizumab
20 Sep 2020 //
BUSINESSWIRE
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization European Commission
29 Jun 2020 //
BUSINESSWIRE
Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS®
24 Jun 2020 //
BUSINESSWIRE
